Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

What is Borrelia burgdorferi p30 – IgM?

The p30 – IgM marker measures early immune system activity against the p30 protein of Borrelia burgdorferi, the bacterium responsible for Lyme disease. The "p30" refers to a 30-kilodalton protein expressed by the bacterium, which serves as one of several antigens used in serologic testing to detect the body’s immune response.

IgM antibodies are produced during the early stages of infection—typically within the first 1 to 2 weeks following exposure. Therefore, the presence of IgM antibodies to the p30 protein may indicate that your immune system is actively responding to a recent or ongoing Borrelia infection.

What Does a Medium Result Mean?

A medium result for Borrelia burgdorferi p30 – IgM indicates a moderate level of IgM antibodies to the p30 protein. This may represent an early immune response, a waning infection, or a nonspecific antibody reaction. While not strongly positive, it suggests some level of immune activity and should be interpreted alongside your symptoms, exposure risk (such as tick bites in a Lyme-endemic area), and results from other Lyme-related markers.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

Outer surface protein A (OspA) is one of the major proteins in the outer membrane of this B. burgdorferi. A vaccine based OspA was approved by the FDA in 1998. Individuals vaccinated subcutaneously showed approximately 76% protection agains B. burgdorferi infection after receiving three vaccine doses; however, the human vaccine was removed from the market later.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

Outer surface protein A (OspA) is one of the major proteins in the outer membrane of this B. burgdorferi. A vaccine based OspA was approved by the FDA in 1998. Individuals vaccinated subcutaneously showed approximately 76% protection agains B. burgdorferi infection after receiving three vaccine doses; however, the human vaccine was removed from the market later.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

Outer surface protein B (OspB) is one of the major proteins in the outer membrane of this B. burgdorferi. OspB was found to be critical for B. burgdorferi adherence and survival within Ixodes ticks.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

B. burgdorferi p66 is an outer membrane spanning protein Oms66. It is proven to be an integral membrane porin because liposome-reconstituted P66 displayed channel-forming activity in planar lipid bilayer assays. P66 has also been shown to function as an adhesin that binds the mammalian cell receptors, B3 chain and B1 chain integrins.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

B. burgdorferi p66 is an outer membrane spanning protein Oms66. It is proven to be an integral membrane porin because liposome-reconstituted P66 displayed channel-forming activity in planar lipid bilayer assays. P66 has also been shown to function as an adhesin that binds the mammalian cell receptors, B3 chain and B1 chain integrins.

The Borrelia burgdorferi p83-93 IgG marker detects the presence of IgG antibodies against a specific protein (p83-93) found in Borrelia burgdorferi, the bacterium that causes Lyme disease. This protein is associated with the late stages of Lyme disease and is considered highly specific to Borrelia.

What does p83-93 mean?

The numbers “p83-93” refer to a protein with a molecular weight of 83 to 93 kilodaltons, which is strongly immunogenic. It is typically expressed during later phases of infection, and the body produces IgG antibodies in response.

Why is this marker important?

A positive p83-93 IgG result may indicate a long-standing or late-stage infection with Borrelia burgdorferi. IgG antibodies generally take weeks to develop, so this marker is not used to detect early infection but rather to assess chronic or past exposure.

The Borrelia burgdorferi p83-93 (IgM) marker tests for IgM antibodies against the p83-93 protein of Borrelia burgdorferi, the bacterium responsible for Lyme disease. IgM antibodies typically appear early in an infection and signal an active or recent immune response.

What does p83-93 mean?

The p83-93 protein is a high molecular weight antigen (83 to 93 kilodaltons) found on Borrelia burgdorferi. It is most often associated with late-stage Lyme disease, although detection of IgM against this protein can occasionally appear in early stages if the immune response is robust.

Borreliella burgdorferi is one of the pathogens of the Borreliella burgdorferi sensu lato complex causing Lyme disease. Lyme disease is a zoonotic, vector-borne disease transmitted by the Ixodes tick. Clinical presentation of Lyme disease is known for the characteristic bull's-eye rash (also known as erythema migrans) but can also include myocarditis, cardiomyopathy, arrythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy depending on the stage of infection.

What is Borrelia burgdorferi VlsE1 – IgM?

The VlsE1 – IgM marker detects early immune system activity against Borrelia burgdorferi, the bacterium that causes Lyme disease. VlsE1 (Variable major protein-like sequence Expressed 1) is a highly specific surface protein used by the bacterium to evade the immune system through antigenic variation. Because of this, VlsE1 is a key target in serological testing for Lyme disease.

IgM antibodies are typically the first type of antibody produced by the immune system in response to an infection. Therefore, a positive or elevated IgM result for Borrelia burgdorferi VlsE1 may indicate recent or current infection.

A medium result for Borrelia burgdorferi VlsE1 – IgM indicates a moderate level of IgM antibodies targeting the VlsE1 protein of the Lyme disease bacterium. This suggests that the immune system has recently encountered the pathogen and is mounting a response, but the antibody levels are not high enough to be considered strongly positive. A medium IgM result may reflect an early or evolving immune response, a past exposure with lingering antibodies, or potentially nonspecific reactivity. On its own, this result does not confirm active Lyme disease and should be interpreted alongside symptoms, exposure history, and other diagnostic markers such as IgG or PCR.